ASX Announcement **19 August 2026**

Managing Director & CEO Transition

SYDNEY, Australia– Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) today announces that Managing Director and CEO Mr John Kelly will step down from his role as both a director of the company and as CEO effective 19 August, 2026, following a Board decision to reposition the Company's executive leadership to reflect its evolving international commercial footprint.

As a co-founder of Atomo, Mr Kelly was key in developing the Company's core technology, launching its initial award-winning HIV product, securing its listing, and establishing its commercial platform internationally. Through his leadership, the Company has undergone significant transformation, expanding its customer base and commercial opportunities across international markets with the majority of the Company's commercial activity and potential now concentrated in the United States and Europe.

In recognition of this accelerating shift, the Board has determined that considering a transition of the Managing Director and CEO to a global position is better aligned with the Company's operational and commercial structure moving forward and has resolved to explore transition executive leadership closer to its core markets. The Board thanks Mr Kelly for his foundational contribution in building the Company from inception to its current international scale.

As a result, the Board has appointed US-based Dr. Cheri Walker as interim CEO, effective immediately. Dr. Walker is very familiar with Atomo and the diagnostics market, having served on the Board of Directors since 2022 and as Chair of the Audit and Risk Committee for the last year. Dr. Walker is a senior executive and entrepreneur with more than twenty-five years' experience working with public and private life science and diagnostic companies and has now become an executive director. Employing year's of experience in financial markets as a stock analyst, commercial execution to meet aggressive growth targets, investor relations, strategy, licensing, M&A, and IVD/IVDR/MDR/MDSAP/ISO13485 quality systems, she has worked as part of and with management teams, private equity and venture firms to develop the best strategies to build their life science business. Dr. Walker's US base reflects the Board's acknowledgement to better align executive leadership with the Company's primary commercial markets.

This appointment also reflects a broader evolution in the Company's leadership requirements, as it moves from a technical and development focus to a more commercial and sales-driven emphasis as it scales its presence in international markets, particularly in the US. Dr. Walkers's experience commercialising life science and diagnostic products in the US and Europe positions her well to lead the Company through this next phase of growth. Additionally, the next phase of growth for Atomo is to build a diagnostic company with a strong and compelling pipeline of its own proprietary products for professional and consumer use, growing from its current focus on being the technology inside other diagnostic companies' products. The Board will commence a formal global search process to appoint a permanent CEO in due course. The key terms of Dr Walker's agreement are included in Appendix 1.

To support a smooth transition, Mr Kelly will has agreed to support Dr. Walker as interim CEO to ensure continuity of leadership and facilitating the transfer of knowledge, key relationships and strategic priorities and the Company has agreed to pay Mr Kelly an additional 3 months' salary for this support

For personal use only

For personal use only

work. The Company has also agreed to pay Mr Kelly 14 weeks' salary on the cessation of his employment as CEO.

Mr Kelly said, *"It has been a privilege for me to lead Atomo since the start, and I'm extremely proud of what we have achieved together. The award-winning products we have developed are increasingly recognised a delivering 'best in class' performance in market. The team at Atomo has helped establish HIV self-testing in a number of countries, including here In Australia and our products continue to improve lives around the world".*

Mr Kelly added, *"With novel tests for Syphilis and Liver function developed and now moving towards commercialisation, I remain excited by the company's future and offer my support and assistance to Dr. Cheri Walker as she steps into the role to deliver the next stage of our commercial growth across global markets."*

Mr Cook, Non-Executive Chair commented:

"The Board acknowledges John Kelly for his outstanding contribution to the Company over the past 15 plus years as its co-founder, inventor, Chief Executive Officer, and the driving force behind its successful ASX listing and the Company's subsequent growth. Through vision, perseverance and entrepreneurial leadership, John established the Company and guided it from an innovative concept to a publicly listed organisation with a strong platform for future growth. The Board sincerely thanks John for his dedication, passion and commitment throughout this remarkable journey. The Company is now entering its next phase of commercial growth, with an increased focus on commercial execution and scaling its market opportunities internationally. On behalf of Atomo's people, shareholders *stakeholders, we express our appreciation to John and wish him every success in his future endeavours."*

"The Board looks forward to supporting Dr Walker in her role as interim CEO. Dr Walker will bring her extensive experience to guide and grow the Company as it expands into the next stage of its commercial growth."

~ ENDS ~

For more information, please contact:

Patrick Cook
Non-Executive Chair
e. queries@atomodiagnostics.com
p. +61 2 9099 4750

This announcement was authorised by the Board.

Appendix 1 - Key Terms of Arrangement with Dr Cheri Walker

Position Title	Interim Chief Executive Officer
Commencement date	19 August 2026
Basis of Employment & Term	Consulting arrangement for an initial fixed term of six months. The agreement may be extended for further six-month periods by mutual agreement.
Total Remuneration	Initial Term of 6-months, the payments will total A$222,500 which is equal to A$37,083 per month. *Note: Dr Walker's Non-Executive Director remuneration fees will continue unchanged.*
Termination	**Termination by the Company:** The Company may terminate immediately, without notice, if the Consultant is unable or refuses to perform the services or materially breaches the agreement. In that case, only fees for services performed and approved expenses incurred up to termination are payable. **Termination by Dr Walker:** Dr Walker may terminate the agreement by giving 90 days' written notice.

For personal use only